Skip to main content
OpenTrials

Clinical trial condition

Myeloproliferative Disorders

Explore clinical trials studying Myeloproliferative Disorders. Study availability and eligibility vary by location and protocol.

506 public trials 83 recruiting studies
Refine in advanced search Browse all conditions

Myeloproliferative Disorders trial results

Active, not recruiting

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • Levine Cancer Institute Charlotte, North Carolina, United States
  • University of Yamanashi Hospital Chūō, Yamanashi, Japan
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View all 73 locations
View Trial Details
Active, not recruiting

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • The University of Alabama At Birmingham Birmingham, Alabama, United States
  • Stanford University Palo Alto, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Northwestern University Chicago, Illinois, United States
View all 30 locations
View Trial Details
Active, not recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +8 more
Locations
  • Royal Brisbane and Women'S Hospital Herston, Queensland, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter Maccallum Cancer Centre Melbourne, Victoria, Australia
  • The Alfred Hospital Melbourne, Victoria, Australia
View all 28 locations
View Trial Details
Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

NCT02506933

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, +43 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, not recruiting

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

NCT04285086

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +7 more
Locations
  • Mayo Clinic - Scottsdale Scottsdale, Arizona, United States
  • Washington University School of Medicine - Division of Oncology St Louis, Missouri, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • University of Utah Salt Lake City, Utah, United States
View all 67 locations
View Trial Details
Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

NCT04603001

Conditions
Acute Myeloid Leukemia (AML), Bone Marrow Diseases, Chronic Disease, +17 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • University of California, Davis - Health Systems Sacramento, California, United States
  • H Lee Moffitt Cancer Center Tampa, Florida, United States
View all 37 locations
View Trial Details
Active, not recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414

Conditions
Anemia, Bone Marrow Diseases, Hematologic Diseases, +5 more
Locations
  • Local Institution - 110 Los Angeles, California, United States
  • Local Institution - 135 Orlando, Florida, United States
  • Local Institution - 133 Plantation, Florida, United States
  • Local Institution - 112 Chicago, Illinois, United States
View all 185 locations
View Trial Details
Active, not recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156

Conditions
Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, +6 more
Locations
  • University of California-San Diego/Moores UCSD Cancer Center La Jolla, California, United States
  • UCLA David Geffen School of Medicine Los Angeles, California, United States
  • Smilow Cancer Center at YNHH New Haven, Connecticut, United States
  • BRCR Medical Center Inc Plantation, Florida, United States
View all 144 locations
View Trial Details

Related conditions